AstraZeneca plc (LON:AZN) had its target price boosted by Jefferies Group LLC from GBX 4,900 ($65.11) to GBX 5,100 ($67.77) in a research note issued to investors on Monday. The firm currently has a hold rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued research reports about the company. UBS AG set a GBX 5,150 ($68.43) target price on AstraZeneca plc and gave the stock a neutral rating in a research report on Tuesday, June 27th. J P Morgan Chase & Co reaffirmed a neutral rating on shares of AstraZeneca plc in a research report on Thursday, July 13th. Credit Suisse Group decreased their target price on AstraZeneca plc from GBX 5,000 ($66.44) to GBX 4,700 ($62.45) and set a neutral rating for the company in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($51.82) target price on AstraZeneca plc and gave the stock a sell rating in a research report on Wednesday, August 2nd. Finally, Shore Capital reissued a hold rating on shares of AstraZeneca plc in a research report on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. AstraZeneca plc currently has an average rating of Hold and an average target price of GBX 5,172.64 ($68.73).

AstraZeneca plc (LON:AZN) opened at 5182.00 on Monday. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00. The stock’s market capitalization is GBX 65.60 billion. The company’s 50-day moving average price is GBX 4,859.28 and its 200 day moving average price is GBX 4,907.26.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/astrazeneca-plc-azn-price-target-raised-to-gbx-5100-at-jefferies-group-llc/1635935.html.

In related news, insider Nazneen Rahman acquired 39 shares of the firm’s stock in a transaction on Thursday, July 27th. The shares were bought at an average cost of GBX 4,370 ($58.07) per share, with a total value of £1,704.30 ($2,264.55).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.